Key recommendation: 7-day treatment duration; de-escalation within 48-72 hours
Shorr MDR Risk Score
Shorr AF, Zilberberg MD, Micek ST, Kollef MH.
Prediction of Infection Due to Antibiotic-Resistant Bacteria by Select Risk Factors for HCAP
Archives of Internal Medicine 2008; 168(20):2205-10
HCAP evidence review
Attridge RT, Frei CR.
Health Care-Associated Pneumonia: An Evidence-Based Review
American Journal of Medicine 2011; 124(7):689.e1-689.e10
Severity scoring in HCAP
Fang WF, Yang KY, Wu CL, et al.
Application and Comparison of Scoring Indices to Predict Outcomes in HCAP
Critical Care 2011; 15(1):R32
Noguchi S, Yatera K, Kawanami T, et al.
Pneumonia Severity Assessment Tools for HCAP: Systematic Review and Meta-Analysis
Respiration 2016; 91(1):16-27
Microbiology laboratory diagnostics
Miller JM, Binnicker MJ, Campbell S, et al.
Guide to Utilization of Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update
IDSA and ASM; Clinical Infectious Diseases 2024; doi: 10.1093/cid/ciae104
Maruyama risk-factor guided strategy
Maruyama T, Fujisawa T, Okuno M, et al.
A New Strategy for Healthcare-Associated Pneumonia
Clinical Infectious Diseases 2013; 57(10):1373-83
File TM, Ramirez JA.
Community-Acquired Pneumonia
New England Journal of Medicine 2023; 389(7):632-641
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.